Literature DB >> 9709385

Systematic review of nebulized antibiotics in cystic fibrosis: evolution of protocol.

S Mukhopadhyay1, M Singh, S Ogston, G Ryan, R Smyth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9709385      PMCID： PMC1296370          DOI： 10.1177/014107689809134S05

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  10 in total

1.  The Cochrane Collaboration: the role of the UK Cochrane Centre in identifying the evidence.

Authors:  C Lefebvre
Journal:  Health Libr Rev       Date:  1994-12

2.  Cystic fibrosis in adolescents and adults.

Authors:  D Mulherin; K Ward; M Coffey; M T Keogan; M FitzGerald
Journal:  Ir Med J       Date:  1991 Dec-1992 Jan

3.  Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Authors:  M E Hodson; A R Penketh; J C Batten
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

4.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.

Authors:  K F Schulz; I Chalmers; R J Hayes; D G Altman
Journal:  JAMA       Date:  1995-02-01       Impact factor: 56.272

5.  The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis.

Authors:  S Mukhopadhyay; G E Staddon; C Eastman; M Palmer; E R Davies; F Carswell
Journal:  Respir Med       Date:  1994-03       Impact factor: 3.415

6.  Quantitative deposition of aerosolized gentamicin in cystic fibrosis.

Authors:  J S Ilowite; J D Gorvoy; G C Smaldone
Journal:  Am Rev Respir Dis       Date:  1987-12

7.  Pseudomonas infection, allergy, and cystic fibrosis.

Authors:  R W Pitcher-Wilmott; R J Levinsky; I Gordon; M W Turner; D J Matthew
Journal:  Arch Dis Child       Date:  1982-08       Impact factor: 3.791

8.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors:  H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

9.  Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks.

Authors:  S Mukhopadhyay; M Singh; J I Cater; S Ogston; M Franklin; R E Olver
Journal:  Thorax       Date:  1996-04       Impact factor: 9.139

10.  Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.

Authors:  P M Mendelman; A L Smith; J Levy; A Weber; B Ramsey; R L Davis
Journal:  Am Rev Respir Dis       Date:  1985-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.